3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
90
Lung Neoplasms
34
Meningeal Carcinomatosis
11
Neoplasms
9
Neoplasm Metastasis
7
Adenocarcinoma of Lung
6
Colorectal Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Mesothelioma, Malignant
4
Non-squamous Non-small Cell Lung Cancer
3
NSCLC
3
Mesothelioma
3
Carcinoma
3
Advanced Solid Tumors
3
Non Squamous Non Small Cell Lung Cancer
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Carcinoma, Bronchogenic
2
Bronchial Neoplasms
2
Breast Neoplasms
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
Docetaxel
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
taxane
1
liposomal doxorubicin
1
durvalumab
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Biosimilar Pharmaceuticals
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Vaccinia
×
Pemetrexed
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled